Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

58.48 -4.28 (-6.82%)
Streaming Delayed Price Updated: 3:23 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
45 46 Next >
The State of Weight Loss Drugs
Via The Motley Fool
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease. 
Via MarketBeat
3 Cold Stocks That Can Bounce Back This Week
These three stocks tumbled by at least 20% last week, but they may not be down for long. 
Via The Motley Fool
MarketBeat Week in Review – 03/03 - 03/07
Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue 
Via MarketBeat
Topics Economy
Forecasting The Future: 15 Analyst Projections For Hims & Hers Health
 
Via Benzinga
Why Hims & Hers Stock Just Collapsed
Via The Motley Fool
Market Whales and Their Recent Bets on HIMS Options
 
Via Benzinga
This Could Be a Huge Blow to Hims & Hers Health Stock
Via The Motley Fool
Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It
Via The Motley Fool
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy. 
Via Benzinga
Novo Nordisk Slashes Wegovy Price, Undercutting Hims & Hers Health
The news slammed Hims stock. Hims & Hers sells knockoff versions of semaglutide, the chemical backbone behind Wegovy. 
Via Investor's Business Daily
Missed the Hims & Hers Rally? Clover Health Could Be Next
After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space. 
Via MarketBeat
Why Hims & Hers Health Stock Sank This Week
Via The Motley Fool
Hims & Hers Health Unusual Options Activity For February 28
 
Via Benzinga
EXCLUSIVE: February's 20 Most-Searched Tickers On Benzinga Pro – Where Do Tesla, Palantir, Alibaba, Nvidia Rank?
These were the 20 tickers that Benzinga readers searched for the most during the month of February. 
Via Benzinga
Tech Sector Hammered As Trump's Tariff Plans Spark Market Selloff: Nvidia, ARM, Super Micro Lead Tech Bloodbath
U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors. 
Via Benzinga
Topics Government World Trade
Short Term Relief Likely
Post earnings has seen little bullish follow-through, and this typically means the broad market won’t have much to shout about over the coming weeks. 
Via Talk Markets
Topics ETFs Stocks / Equities
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?
Via The Motley Fool
Sixty Percent Of The Time, It Works Every Time
​​​​​​​The past few weeks have brought a dramatic change in investor sentiment. 
Via Talk Markets
Topics Stocks / Equities
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up
Can Hims & Hers Health recover after the FDA removed semaglutide from its drugs shortage list? 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
NVDA Earnings And The State Of The Market
Nvidia reported its much anticipated 4Q earnings after the close. It was a mixed bag. 
Via Talk Markets
Topics Stocks / Equities
Why Hims & Hers Stock Rebounded on Wednesday
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now
See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes. 
Via MarketBeat
GoodRx Earnings: What To Look For From GDRX
Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results tomorrow before the bell. Here’s what investors should know. 
Via StockStory
Dow Surges 200 Points; Keurig Dr Pepper Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Hims & Hers Health Analyst Sees Buying Opportunity Following Steep Selloff: 'We See No Reason To Change Our View'
Hims & Hers Health Inc. (NYSE: HIMS) shares dropped sharply after the company reported its fourth-quarter earnings. Here's what you need to know. 
Via Benzinga
Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected,... 
Via StockStory
Which stocks are experiencing notable movement on Tuesday?
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.